UNSPSC 51142420: Ergotamine

This classification denotes a serotonin agonist with the molecular formula C33H35N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PR834Q503T, chemically known as 5-benzyl-12-hydroxy-2-methyl-3,6,18-trioxoergotaman but generally known as ergotamine, which bears US NIH Compound Identifier 3251. European Medicines Agency schedules Ergotamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06598MIG.

UNSPSC 51142420 Ergotamine is a Commodity code nominally designating a specific pharmaceutical active ingredient, but recent state and local opportunities posted under this code reflect broader pharmaceutical procurement across multiple product categories, including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The work involves establishing supply contracts for pharmaceutical products with quarterly or ongoing deliveries to public health facilities, compliance with FDA manufacturing standards and drug supply chain security requirements, and electronic ordering and delivery through authorized wholesalers or direct manufacturer relationships. Vendors must demonstrate cGMP certification, Drug Supply Chain Security Act compliance, established relationships with licensed pharmaceutical wholesalers, and appropriate insurance coverage including commercial general liability and professional liability.

Recent activity spans Florida, Texas, and Minnesota-based cooperative purchasing structures. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023 (response deadline). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline, requiring vendors to work through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and certify cGMP and DSCSA compliance; the MMCAP contract carries a two-year initial term with performance penalties of $200 to $1,500 per violation and a 3 percent administrative fee on all purchases.